We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

38 hedge funds and large institutions have $36.6M invested in Pyxis Oncology in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

1.83% less ownership

Funds ownership: 61.04% → 59.21% (-1.8%)

3% less funds holding

Funds holding: 39 → 38 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

23% less capital invested

Capital invested by funds: $47.7M → $36.6M (-$11.1M)

Holders
38
Holders Change
-1
Holders Change %
-2.56%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$2.22M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$206K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$178K
4
Renaissance Technologies
Renaissance Technologies
New York
+$140K
5
BCM
Bridgeway Capital Management
Texas
+$131K

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$2.13M
2
RI
RTW Investments
New York
-$1.62M
3
RCM
RA Capital Management
Massachusetts
-$493K
4
Millennium Management
Millennium Management
New York
-$138K
5
E
Ergoteles
New York
-$87K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$49K – – –
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$46K – – –
Bank of America
28
Bank of America
North Carolina
$40K +$11.4K +4,353 +28%
Charles Schwab
29
Charles Schwab
California
$35K +$46.3K +17,739 New
TRCT
30
Tower Research Capital (TRC)
New York
$31K +$33.1K +12,676 +414%
Tudor Investment Corp
31
Tudor Investment Corp
Connecticut
$27K – – –
PCM
32
Prelude Capital Management
New York
$22K +$28.9K +11,052 New
Two Sigma Advisers
33
Two Sigma Advisers
New York
$20K +$27.2K +10,400 New
Fidelity Investments
34
Fidelity Investments
Massachusetts
$2K -$8 -3 -0.3%
O
35
OrbiMed
New York
$1.67K +$2.22M +848,252 New
RI
36
RTW Investments
New York
– -$1.62M -682,220 Closed
E
37
Ergoteles
New York
– -$87K -36,415 Closed
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
– -$34K -14,466 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$31K -12,882 Closed
Legal & General Group
40
Legal & General Group
United Kingdom
– -$2K -833 Closed
UBS Group
41
UBS Group
Switzerland
– -$554 -212 -58%
Wells Fargo
42
Wells Fargo
California
– +$199 +76 +109%
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
– +$502 +192 New
1
2

PYXS Hedge Fund Activity: Q3 2022 in Review

38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2022, worth a combined $36.6M — down 23% from $47.7M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PYXS and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 13 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $2.22M. The largest seller was Credit Suisse, cutting an estimated $2.13M.

  • 38 institutional investors held Pyxis Oncology (PYXS) as of Q3 2022, down from 39 in Q2 2022.
  • Funds reported $36.6M of Pyxis Oncology stock for Q3 2022, down 23% quarter-over-quarter.
  • 5 funds opened new Pyxis Oncology positions in Q3 2022 and 6 closed out, a net change of -1 holder.
  • The largest Pyxis Oncology buyer in Q3 2022 was OrbiMed, an estimated $2.22M added.
  • The largest Pyxis Oncology seller in Q3 2022 was Credit Suisse, an estimated $2.13M sold.

Based on aggregated 13F filings for Q3 2022.